ABSTRACT
Background: The increase in CVS morbidity and mortality could be significantly reduced by control of SBP and DBP, as well as reduction in Hyperlipidemia.Methods: The patients of stage-1 HTN with either sex according to JNC VII criteria were included and were followed up every 2 weeks from baseline upto 12 weeks. The randomized patients were divided into two groups to receive beta blocker viz. Atenolol 50 mg (group A, N=50) and ARB Olmesartan medoxomil 40 mg (group B, N=50).Results: The average Total cholesterol measured among Group A subjects was significantly increased by 1.8% by the end of 12th week whereas the average cholesterol measured among Group B subjects at baseline period was reduced by 7.9% after 12 weeks therapy. The average HDL measured among Group A subjects at baseline period significantly reduces by 5.9% by the end of 12th week whereas the HDL levels measured among Group B subjects at baseline period was significantly increased by after 12 weeks therapy. The average Triglyceride (TG) levels measured among Group A subjects at baseline period was significantly increased by 12.4% by the end of 12th week whereas the Triglyceride (TG) levels measured among Group B subjects at baseline period was significantly reduced by 9.5% after 12 weeks therapy. The average LDL levels measured among Group A subjects at baseline period was significantly increased by 1.5% by the end of 12thweek whereas the average LDL measured among Group B subjects at baseline period was significantly reduced by 11.2% to after 12 weeks therapy. The average VLDL levels measured among Group A subjects at baseline period was significantly increased by 12.4% by the end of 12th week whereas the average VLDL measured among Group B subjects at baseline period was significantly reduced by 9.5% after 12 weeks therapy.Conclusions: ARB- Olmesartan medoxomil is a better drug than beta blocker-Atenolol as it leads to greater deduction in lipid profile.
ABSTRACT
Background: Diabetes mellitus is a major public health problem. It is worldwide & a major risk factor for cardiovascular diseases. Glibenclamide and Glimepiride are widely used second generation sulfonylurea antidiabetic drugs. Both Glibenclamide and Glimepiride stimulate release of insulin from pancreatic acinar cells, by blocking an ATP-sensitive potassium channel. Therefore we evaluated the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin in patients of type II diabetes mellitus. Aims & Objective: (1) To find out the demographic profile of type II diabetes mellitus. (2) To find out the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin (HbA1c) in type II diabetes mellitus Patients. (3) To compare the effect of Glimepiride and Glibenclamide on glycosylated haemoglobin (HbA1c) among the two study groups. Material and Methods: A prospective, randomized, open, parallel group study was carried out in patients attending OPD of Medicine department MM Institute of Medical Sciences and Research (MMIMSR), Mullana, Ambala. 50 patients were randomly assigned into groups A & group B. In Group A (n=25) Glibenclamide (5-15 mg/day) & in Group B (n=25) Glimepiride (1-6 mg/day) was administered for a period of 24 weeks. Data analyzed by Student’s “t”- test. Results: It was found that prevalence of type II diabetes mellitus is more common among the male patients There was a significant reduction in glycosylated haemoglobin score (p<0.05) in both the study groups after 24 weeks but glycosylated haemoglobin level did not differ significantly (p>0.05) between the two groups. Conclusion: Glibenclamide and Glimepiride lowered glycosylated haemoglobin to a similar degree without significant difference between the two groups.